A panel of investigational monoclonal antibodies (mAbs) targeting different sites of the Epstein-Barr virus (EBV) blocked infection when tested in human cells in a laboratory setting. Moreover, one of the experimental mAbs ...
Oct 27, 2022
0
34
Using a novel response-adapted ultra-low dose radiation therapy strategy, researchers at The University of Texas MD Anderson Cancer Center observed a 90% complete response rate in patients with orbital indolent B-cell lymphoma. ...
Oct 24, 2022
0
5
Patients with Hodgkin lymphoma (HL) are more likely to suffer from mental-health and substance-abuse disorders than the general population. Calling for more attention to mental health, a study published August 2 in Cancer ...
Aug 15, 2022
0
10
Individuals without private health insurance coverage are more likely to be diagnosed with late-stage cancer and have worse survival, according to a study published online July 13 in CA: A Cancer Journal for Clinicians.
Jul 13, 2022
0
6
There is considerable variation in the management of mantle cell lymphoma across different clinical settings, and some strategies do not always conform with what might be expected, according to an analysis by investigators ...
Jun 28, 2022
0
5
Combination chemoimmunotherapy with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free survival over standard chemoimmunotherapy for previously untreated mantle cell lymphoma (MCL) ...
Jun 3, 2022
0
35
Roughly 620,000 new cases of lymphoma were diagnosed worldwide, according to the World Cancer Research Fund International's 2020 report. Survival rates have improved as advances develop in treatment, such as chimeric antigen ...
Apr 5, 2022
0
11
(HealthDay)—For patients with lymphoid malignancies undergoing autologous hematopoietic stem cell transplantation (aHSCT), frailty is associated with worse hospital outcomes, according to a study published online Dec. 23 ...
Jan 24, 2022
0
19
Of the 18,000 people diagnosed with large B-cell lymphoma each year, only half will be successfully treated with chemotherapy. The 9,000 remaining patients typically have poor outcomes, with only 25% responding to additional, ...
Dec 13, 2021
0
1
Three clinical studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated enhanced responses for patients with high-risk lymphoma treated with axicabtagene ciloleucel (axi-cel) chimeric antigen ...
Dec 12, 2021
0
3
